AGILE: A phase 3, multicenter, randomized, placebo-controlled study of ivosidenib in combination with azacitidine in adult patients with previously untreated acute myeloid leukemia with an IDH1 mutation.

被引：6
|
作者：
Stein, Eytan
Dinardo, Courtney Denton
Jang, Jun Ho
Miyazaki, Yasushi
Martinez, Roberto Ovilla
Auer, Julia
Zhang, Vickie
Koralek, Daniel O.
Wu, Bin
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] Sungkyunkwan Univ, Samsung Med Ctr, Dept Hematol Oncol, Sch Med, Seoul, South Korea
[4] Univ Nagasaki, Nagasaki, Japan
[5] Hosp Angeles Lomas, Huixquilucan, Mexico
[6] Agios Pharmaceut Inc, Cambridge, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.TPS7074
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS7074
引用
收藏
页数：2
相关论文
共 50 条
  • [1] AGILE: A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Ivosidenib in Combination with Azacitidine in Adult Patients with Previously Untreated Acute Myeloid Leukemia with an IDH1 Mutation
    Montesinos Fernandez, Pau
    Recher, Christian
    Doronin, Vadim
    Calado, Rodrigo T.
    Jang, Jun Ho
    Miyazaki, Yasushi
    Wang, Jianxiang
    Gianolio, Diego A.
    Daigle, Scott R.
    Winkler, Thomas
    Zhang, Vickie
    Paschka, Peter
    BLOOD, 2019, 134
  • [2] AGILE: A Global, Randomized, Double-Blind, Phase 3 Study of Ivosidenib plus Azacitidine Versus Placebo plus Azacitidine in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation
    Montesinos, Pau
    Recher, Christian
    Vives, Susana
    Zarzycka, Ewa
    Wang, Jianxiang
    Bertani, Giambattista
    Heuser, Michael
    Calado, Rodrigo T.
    Schuh, Andre C.
    Yeh, Su-Peng
    Daigle, Scott R.
    Hui, Jianan
    Zhang, Vickie
    Pandya, Shuchi S.
    Gianolio, Diego A.
    de Botton, Stephane
    Doehner, Hartmut
    BLOOD, 2021, 138
  • [3] AGILE: A Global, Randomized, Double-Blind, Phase 3 Study of Ivosidenib plus Azacitidine Versus Placebo plus Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia With an IDH1 Mutation
    Dohner, Hartmut
    Montesinos, Pau
    Polo, Susana Vives
    Zarzycka, Ewa
    Wang, Jianxiang
    Bertani, Giambattista
    Heuser, Michael
    Calado, Rodrigo T.
    Schuh, Andre C.
    Yeh, Su-Peng
    de la Fuente, Adolfo
    Cerchione, Claudio
    Daigle, Scott R.
    Hui, Jianan
    Pandya, Shuchi S.
    Gianolio, Diego A.
    Recher, Christian
    de Botton, Stephane
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S234 - S234
  • [4] FDA Approval Summary: Ivosidenib in Combination with Azacitidine for Treatment of Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation
    Woods, Ashley
    Norsworthy, Kelly J.
    Wang, Xin
    Vallejo, Jonathon
    Chow, Edwin Chiu Yuen
    Li, Ruo-Jing
    Sun, Jielin
    Charlab, Rosane
    Jiang, Xiling
    Pazdur, Richard
    Theoret, Marc R.
    de Claro, R. Angelo
    CLINICAL CANCER RESEARCH, 2024, 30 (07) : 1226 - 1231
  • [5] Ivosidenib-azacitidine in acute myeloid leukemia with IDH1 R132 mutation
    Mechelfekh, Yaquine
    Gastaud, Lauris
    BULLETIN DU CANCER, 2023, 110 (12) : 1232 - 1233
  • [6] AGILE: Ivosidenib plus azacitidine versus placebo plus azacitidine in patients with newly diagnosed AML with an IDH1 mutation
    Murthy, Vidhya
    Dohner, Harmut
    Montesinos, Pau
    Polo, Susana Vives
    Zarzycka, Ewa
    Heuser, Michael
    Recher, Christian
    De Botton, Stephane
    Hui, Jianan
    Gianolio, Diego
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 : 7 - 7
  • [7] A Randomized, Placebo-Controlled, Phase II Study of Pracinostat in Combination with Azacitidine (AZA) in Patients with Previously Untreated Myelodysplastic Syndrome (MDS)
    Garcia-Manero, Guillermo
    Berdeja, Jesus G.
    Komrokji, Rami S.
    Essell, James
    Lyons, Roger M.
    Maris, Michael
    DeZern, Amy E.
    Sekeres, Mikkael A.
    Roboz, Gail J.
    BLOOD, 2015, 126 (23)
  • [8] Phase 3, randomized, placebo-controlled trials evaluating glasdegib in combination with intensive or nonintensive chemotherapy in patients with untreated acute myeloid leukemia.
    Cortes, Jorge E.
    Dombret, Herve
    Merchant, Akil Abid
    Tauchi, Tetsuzo
    DiRienzo, Christine
    Zeremski, Mirjana
    Sleight, Barbara
    Zhang, Xiaoxi
    Shaik, Mohammed Naveed
    Bell, Timothy
    Chan, Geoffrey
    Sekeres, Mikkael A.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [9] ClarIDHy: A phase 3, multicenter, randomized, double-blind study of AG-120 vs placebo in patients with an advanced cholangiocarcinoma with an IDH1 mutation.
    Lowery, Maeve Aine
    Abou-Alfa, Ghassan K.
    Valle, Juan W.
    Kelley, Robin Kate
    Goya, Lipika
    Shroff, Rachna T.
    Javle, Milind M.
    Borad, Mitesh J.
    Cleary, James M.
    El-Khoueiry, Anthony B.
    Bendell, Johanna C.
    Macarulla, Teresa
    Vogel, Arndt
    Korth, Christopher
    Jiang, Liewen
    Gliser, Camelia
    Wu, Bin
    Agresta, Samuel V.
    Pandya, Shuchi Sumant
    Zhu, Andrew X.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [10] Molecular Measurable Residual Disease in Patients with Newly Diagnosed m IDH1 Acute Myeloid Leukemia Treated with Ivosidenib plus Azacitidine
    DiNardo, Courtney D.
    Marchione, Dylan
    Heuser, Michael
    Hui, Jianan
    Gianolio, Diego
    Daigle, Scott
    Choe, Sung
    Patel, Prapti
    De Botton, Stephane
    Dohner, Hartmut
    BLOOD, 2023, 142
12345